Pharmaceuticals

Global Neutropenia Biologic Drug Treatment Market Analysis For 2026–2030 With Strategic Insights

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Neutropenia Biologic Drug Treatment Market During The Forecast Period?

The neutropenia biologic drug treatment market has experienced substantial growth in recent years. It is projected to expand from $14.78 billion in 2025 to $15.79 billion in 2026, with a compound annual growth rate (CAGR) of 6.8%. The increase observed in the past can be attributed to an uptick in cancer chemotherapy usage, the approval of filgrastim-based therapies, a rise in infection-related hospitalizations, the integration of supportive oncology care, and the standardization of hospital protocols.

The neutropenia biologic drug treatment market size is anticipated to experience substantial growth in the coming years. It is projected to expand to $20.88 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. This increase over the forecast period is attributable to an expanding oncology patient population, greater biosimilar market penetration, the demand for long-acting formulations, the enlargement of outpatient cancer care services, and rising healthcare expenditure. Noteworthy trends during this period include an increased application of G-CSF biologics, a growing adoption of long-acting biologic therapies, advancements in managing chemotherapy-induced neutropenia, a strategic focus on biosimilars for cost reduction, and the expansion of distribution through hospital and oncology pharmacies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3456&type=smp

What Factors Are Contributing To The Growth Of The Neutropenia Biologic Drug Treatment Market?

The global increase in cancer cases is expected to contribute to the market growth for neutropenia biologic drugs. A rising incidence of cancer and an increasing number of individuals opting for chemotherapy have led to a greater prevalence of people suffering from neutropenia. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, an estimated 165,000 Australians were newly diagnosed with cancer, which equates to over 450 cases each day, and males represented about 55% of these diagnoses. Therefore, the global rise in cancer incidence rates is anticipated to boost demand for the neutropenia biologic drug treatment market over the forthcoming years.

How Are Different Segments Classified In The Neutropenia Biologic Drug Treatment Market Segment Analysis?

The neutropenia biologic drug treatment market covered in this report is segmented –

1) By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim

2) By Treatment Type: Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types

3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

What Market Trends Are Affecting The Neutropenia Biologic Drug Treatment Market?

Leading companies in the neutropenia biologic drug treatment sector are focusing on biosimilar development to provide more economical options compared to current biologics. Biosimilars are defined as biologic medications designed to be highly similar to an already approved reference biologic, ensuring comparable safety and efficacy. As an illustration, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical firm, introduced Fylnetra (pegfilgrastim-pbbk), which is a biosimilar to Neulasta, intended for the management and prevention of febrile neutropenia in individuals undergoing chemotherapy. Its mechanism involves binding to specific receptors on hematopoietic cells, thereby stimulating the proliferation and differentiation of neutrophil precursors within the bone marrow. This action leads to an increased production of neutrophils, which are vital for combating infections, particularly in patients undergoing myelosuppressive chemotherapy, consequently lowering the occurrence of febrile neutropenia linked with cancer treatments.

Who Are The Companies Driving Activity In The Neutropenia Biologic Drug Treatment Market?

Major companies operating in the neutropenia biologic drug treatment market are Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy’s Laboratories Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.

Get The Full Neutropenia Biologic Drug Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

Which Geographic Region Dominates The Neutropenia Biologic Drug Treatment Market?

North America was the largest region in the neutropenia biologic drug treatment market in 2025. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neutropenia Biologic Drug Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

Browse Through More Reports Similar to the Global Neutropenia Biologic Drug Treatment Market 2026, By The Business Research Company

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Pegfilgrastim Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market

Orthopedic Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthopedic-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795